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assessed by the clinician was evaluated using areas under the
ROC curve. RESULTS: After item reduction and scoring,
QUARTIS-Start included 28 items grouped into 6 dimensions: 2
Disease Severity dimensions (Symptoms and Daily Allergy) and
4 Treatment Perception dimensions (Reasons for following
Immunotherapy, Advantages, Inconvenience, and Information).
QUARTIS-Follow-up included 27 items grouped into 7 dimen-
sions: 2 Disease Severity dimensions and 5 Treatment Perception
dimensions (Ease of Intake, Inconvenience, Satisfaction, Side-
Effects, and Continuation). Internal consistency was good (Cron-
bach’s alpha coefﬁcients: between 0.66 and 0.78). The predictive
values of the QUARTIS-Follow-up score for patients’ intentions,
patients’ motivations and patients’ adherence (evaluated by the
clinician) were respectively 0.826, 0.770, and 0.653. CON-
CLUSION: QUARTIS is the ﬁrst self-reported questionnaire
assessing patients’ perceptions of SLIT, before and during the
treatment. It demonstrates good predictive value and appears to
be a promising patient-management tool for use in clinical prac-
tice. Further psychometric and linguistic validation steps are
being conducted.
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OBJECTIVES: The Chronic Respiratory questionnaire—Self
Administered Standardized form (CRQ-SAS), a validated health
related quality of life instrument for patients with COPD, was
developed in U.S. and Canadian English to assess this impact.
Prior to use in an international study our team translated the
CRQ-SAS into 11 languages according to a rigorous protocol
ensuring conceptual equivalence and cultural relevance across
languages. METHODS: A specialist conducted the translation
process in each target country following an internationally rec-
ognized methodology: 1) two forward translations and their rec-
onciliation by native speakers of the target language and ﬂuent
in English; 2) backward translation by a native English speaker;
3) review by a clinician; and 4) comprehension test on ﬁve indi-
viduals with COPD. RESULTS: The process revealed two chal-
lenges: the translation of terms with a large semantic ﬁeld (e.g.
“upset”) and the translation of idiomatic expressions such as
“down in the dumps”. Together with the developers of the
instrument we found appropriate language versions to convey
the original concepts. CONCLUSION: We established 11 trans-
lations of the CRQ-SAS according to rigorous methodology. 
The availability of the CRQ-SAS in many languages facilitates
efforts to collect patient data across countries and enables
researchers to compare the impact of COPD on people’s lives
internationally.
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OBJECTIVES: To validate the Chronic Obstructive Pulmonary
Disease Severity Score (COPDSS), a severity screening tool spe-
ciﬁc to COPD patients, for use in the Spanish primary health
care system. METHODS: Cross-sectional, multicenter study,
which included clinically stable COPD patients, with a recent
spirometry, and a diagnosis of COPD based on a FEV1(%)
<80% predicted. All patients provided signed informed consent
to participate. Data on current respiratory symptoms and
number of COPD exacerbations in the previous 12 months were
collected, and patients were classiﬁed using the Medical Research
Council (MRC) dyspnea scale. The COPDSS was administered
by physicians in face-to-face interviews, and patients’ most
recent FEV1 values were recorded. Concurrent validity of the
COPDSS was evaluated by examining the association between
COPDSS scores and dyspnea status, number of exacerbations in
the last 12 months, and FEV1(%). Receiver Operating Charac-
teristics (ROC) curves were used to test the score’s sensitivity and
speciﬁcity. RESULTS: For this preliminary analysis, data was
available from a total of 292 predominantly male (86%) patients
(mean age = 67 years) reporting daily cough (71%), expectora-
tion (74%), progressive dyspnea (60%) having 2 exacerbations
per year as a mean. A moderate correlation was found between
FEV1(%) and COPDSS (r = −0.331, p < 0.001), though COPDSS
correlated more strongly with current dyspnea status (r = 0.595,
p < 0.001) and number of exacerbations in the past 12 months
(r = 0.510, p < 0.001). The instrument discriminated between
patients with varying degrees of dyspnea (grades 0, 1 or 2 vs
grades 3 or 4 on the MRC scale; area under the ROC curve =
0.867), and between patients deﬁned according to number of
exacerbations in the last 12 months (0–2 vs > = 3; area under
ROC curve = 0.787). CONCLUSIONS: This preliminary analy-
sis indicates that the COPDSS is likely to be a useful tool in
primary health care in Spain.
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OBJECTIVES: Existing pre-scored multi-attribute health status
classiﬁcation systems do not capture well the typical impairments
and ﬂuctuating nature of COPD. This study aimed to develop
COPD health proﬁles that describe the health status of these
patients over the course of one year and have these proﬁles
valued by the general population. METHODS: We developed 16
COPD health proﬁles. Each proﬁle combines a description of the
severity of COPD during the stable phase (in terms of symptoms,
impact on non-strenuous and strenuous activities, ability to
work, anxiety and depression, energy and tiredness) with a
description of the exacerbation proﬁle (in terms of frequency,
duration, severity of increase in respiratory and non-respiratory
symptoms, impact on daily activities, and response to treatment).
These proﬁles were valued by a representative sample of the
adult Dutch population using a Visual Analogue Scale (VAS) and
Time Trade Off (TTO). All respondents valued 10 COPD pro-
ﬁles during group sessions. Subsequently all respondents received
a questionnaire to value another 10 COPD proﬁles at home.
Respondents also valued 4 EQ-5D states. RESULTS: A total of
239 respondents attended the group sessions; 235 completed the
questionnaire. Both VAS and TTO values consistently decreased
as severity of COPD increased. When including all available
responses, mean VAS scores ranged from 0.84 (SD 0.12) for mild
COPD without exacerbations to 0.18 (SD 0.12) for very severe
COPD with one non-severe and one severe exacerbation per year.
Mean TTO values were signiﬁcantly higher and ranged from
0.98 (SD 0.09) to 0.43 (SD 0.27), respectively. Overall, within
each COPD severity stage, the utility decrement for exacerba-
